- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Healthcare Executives Share Strategy for Value-Based Care: Population Management
Midas+ Solutions, a healthcare company specializing in quality management, asked C-level healthcare executives to define population health management.
Midas+ Solutions, a healthcare company specializing in quality management, conducted a poll of C-level healthcare executives at it's annual symposium. Representing more than 480 hospitals, the executives were asked to present their perspective on population health management and the factors that define it. The gist of most definitions was what is reverberating across different healthcare systems: facilitating care across the healthcare continuum and highest quality care at the lowest cost.
The executives ranked the factors in the following order:
- Facilitates care across the health continuum
- Supports providing the highest quality of care at the lowest cost
- Uses actionable insight for patient care based on a variety of data
- Targets a specific population of individuals
- Enables patient engagement
Based on their responses, most healthcare organizations are already on top of the game: 65% responders were confident that their organization will deliver fully-scaled population health management programs within 5 years, while 16% indicated that they active population management programs in their organization.
Read more at HIStalk PRACTICE: http://bit.ly/1Iqg3yD
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Functional Similarity Between Ustekinumab Biosimilar ABP 654, Stelara in Crohn Disease
March 10th 2025Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the biosimilar's FDA approval.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
